Page 27 - Expanded Access Program News Today

/PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that due to demand,...

Share this article TEL AVIV, Israel and RALEIGH, N.C,, Jan. 11, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or "the Company"), a specialty biopharmaceutical company, today reported that its partner, Cosmo Pharmaceuticals (SIX: COPN) ("Cosmo"), announced that it had successfully completed their Phase 2 Proof-of-Concept (POC) clinical trial of Rifamycin SV-MMX 600mg in patients with diarrhea-predominant irritable bowel syndrome (IBS-D).  As part of an exclusive license...

Share this article Share this article RADNOR, Pa. and GENEVA, Jan. 11, 2021 /PRNewswire/ -- NeuroRx, Inc. and RELIEF THERAPEUTICS Holding AG (SIX: RLF,OTCQB: RLFTF) ("Relief"), and the Quantum Leap Healthcare Collaborative ("Quantum Leap") of San Francisco announce that NeuroRx and QLHC have signed a Clinical Trial Participation Agreement for the inclusion of ZYESAMI™ (RLF-100 TM: aviptadil) in the I-SPY COVID-19 Clinical Trial.  Quantum Leap is the sponsor of the I-SPY COVID-19 Trial,...

/PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it has entered...

Credit: RedHill Biopharma Preliminary data from the non-powered U.S. Phase 2 study of 40 hospitalized patients shows that orally-administered opaganib was safe, with no material safety differences between opaganib and control arms Consistent trends demonstrate greater improvement in reducing oxygen requirement by end of treatment at Day 14 in the opaganib-treated arm across key primary and secondary efficacy outcomes, correlating with clinical improvement as defined by the World Health Organiz...

(2) Preliminary data from the non-powered U.S. Phase 2 study of 40 hospitalized patients shows that orally-administered opaganib was safe, with no material safety differences between opaganib and control arms Consistent trends demonstrate greater improvement in reducing oxygen requirement by end of treatment at Day 14 in the opaganib-treated arm across key primary and secondary efficacy outcomes, correlating with clinical improvement as defined by the World Health Organization (WHO) ordinal sca...

Share this article Share this article RADNOR, Pa. and GENEVA, Switzerland, Dec. 30, 2020 /PRNewswire/ -- NeuroRx, Inc. and RELIEF THERAPEUTICS Holding AG (SIX: RLF,OTCQB: RLFTF) ("Relief") today announced the conclusion of enrollment in the phase 2b/3 trial of ZYESAMI™ (previously RLF-100 TM: aviptadil) for the treatment of Respiratory Failure in patients with Critical COVID-19 (www.clinicaltrials.gov NCT04311697). No drug-related serious adverse events have been reported as of today. E...

TMCnet News Pluristem Enters Collaboration With Pharmaceutical Company Innovare R&D to Expand Pluristems ARDS Associated With COVID-19 Program to Mexico [December 29, 2020] Pluristem Enters Collaboration With Pharmaceutical Company Innovare R&D to Expand Pluristems ARDS Associated With COVID-19 Program to Mexico HAIFA, Israel, Dec. 29, 2020 (GLOBE NEWSWIRE) -- (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic products, ann...

BrainStorm Issues 2020 Letter to Shareholders USA - English Share this article Share this article NEW YORK, Dec. 28, 2020 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI),  a leading developer of cellular therapies for neurodegenerative diseases, today announced the following letter from its Chief Executive Officer, Chaim Lebovits, to its shareholders and the investment community. Dear Valued Shareholders, I am incredibly proud of the tremendous progress BrainStorm made as a...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Chiesi Global Rare Diseases Announces First Patient Treated in Expanded Access Program for ... Chiesi USA, Inc.December 23, 2020 GMT - Program grants access to investigational therapy for Fabry disease patients in the United States who cannot be adequately treated with currently available FDA-approved drugs - BOSTON, Dec. 23, 2020 (GLOBE NEWSWIRE) -- Chiesi Global Rare Diseases, a business unit of Chi...